Oscotec Inc.

Rm A-901 9/F Koreabiopark, Seongnam, Gyeonggi, South Korea

Clinical Trials

6 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

76.9%

Phase 2

15.4%

Early Phase 1

7.7%

Trial Status Distribution

Active, not recruiting

46.1%

Completed

46.1%

Recruiting

7.7%

Clinical Trials

Trials sponsored by this organization (13)

Bioequivalence Study of SKI-O-703 in Healthy Adults Under Fed Conditions

Phase 1

Active, not recruiting

interventional

Jul 202648 participants

Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors

Phase 1

Recruiting

interventional

Dec 202551 participants

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SKI-G-801 in Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

interventional

Jan 202236 participants

A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects

Early Phase 1

Completed

interventional

Aug 20218 participants

Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)

Phase 2

Completed

interventional

Oct 201961 participants

Efficacy and safety of oral SKI-O-703 in persistent and chronic immune thrombocytopenia

Phase 1

Active, not recruiting

Aug 201960 participants

Efficacy and safety of oral SKI-O-703 in persistent and chronic immune thrombocytopenia

Phase 1

Active, not recruiting

Jul 201960 participants

Efficacy and safety of oral SKI-O-703 in persistent and chronic immune thrombocytopenia

Phase 1

Active, not recruiting

Jun 201960 participants

Page 1 of 2

Approvals

No approval data available

News

No news articles found

Back to Organizations